GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Seaport Therapeutics, Inc. Common Stock SPTX · USD

US listing · 🇺🇸 United States

Compare

21.93

+1.98%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Seaport Therapeutics, Inc. Common Stock

Its shares trade under the ticker SPTX. It has been listed since 1 May 2026.

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
1 May 2026
Head office
6 TIDE STREET, BOSTON, MA, 02110
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Seaport Therapeutics' Glyph technology platform enables oral bioavailability for neuropsychiatric medicines.
  • The company focuses exclusively on neuropsychiatric medicines using its proprietary platform.
  • Founded in 2024, Seaport Therapeutics has a clear R&D focus on depression and anxiety disorders.

Weaknesses

  • The company is a clinical-stage biopharmaceutical firm with no approved products yet.
  • Seaport Therapeutics has limited financial resources as a newly founded company.
  • All therapeutic candidates are based on a single platform, increasing development risk.

Opportunities

  • The growing neuropsychiatric medicine market offers significant expansion potential.
  • Seaport Therapeutics can leverage its Glyph platform for additional therapeutic applications.
  • Collaborations with key opinion leaders in healthcare sectors may accelerate development.

Threats

  • Regulatory hurdles in the biopharmaceutical industry could delay product approval.
  • Competition from established biotech firms in the neuropsychiatric sector remains high.
  • Clinical trial failures could impact the company's development pipeline significantly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.